BIXINK THERAPEUTICS
BIXINK Therapeutics creates a new treatment paradigm with creativity and innovation. The company intends to become a company that becomes the source of a healthier life through the construction and convergence of technology that encompasses the times.
BIXINK THERAPEUTICS
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Content Delivery Network Font Awesome Mobile Non Scaleable Content Nginx Amazon Organization Schema Person Schema
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2021-12-07 | Limbix | BIXINK Therapeutics investment in Series A - Limbix | 15 M USD |
2020-05-05 | Limbix | BIXINK Therapeutics investment in Series A - Limbix | 9 M USD |
More informations about "BIXINK Therapeutics"
BIXINK
May 24, 2020 BIXINK, Breast cancer adjuvant treatment 'Nerlynx' has entered into Big 5 General Hospital 0 0 21 Sep 2022 ... 0 0 20 Jul 2022 Views 4733 Bixink Therapeutics signs deals to โฆSee details»
๋น ์ฝํฌ l BIXINK
๋น ์ฝํฌ, ็พ ์ฒญ์๋ ์ฐ์ธ์ฆ ๋์งํธ ์น๋ฃ์ ๊ตญ๋ด ๋ ์ ๊ณ์ฝ ์ฒด๊ฒฐSee details»
BIXINK Therapeutics - Crunchbase Investor Profile & Investments
BIXINK Therapeutics creates a new treatment paradigm with creativity and innovation. The company intends to become a company that becomes the source of a healthier life through the โฆSee details»
BIXINK Therapeutics investment portfolio - PitchBook
BIXINK Therapeutics General Information Company Description. Founded in 2016, BIXINK Therapeutics is a venture capital investment firm based in Seoul, South Korea. The firm seeks โฆSee details»
BIXINK Therapeutics - Investments, Portfolio & Company Exits
BIXINK Therapeutics has had . obfuscated. obfuscated. exit, which was Limbix. Which industries has this organization had the most exits in? Show . Limbix Limbix is a prescription digital โฆSee details»
Subsidiaries of KPS - kpscorp.co.kr
BIXINK. BIXINK THERAPEUTICS is a new biopharmaceutical company aiming to develop a new treatment paradigm with creativity and innovation. The global market for therapeutic agents, โฆSee details»
Bixink Therapeutics signs deals to expand DTx pipelines
May 24, 2022 Bixink Therapeutics is accelerating efforts to build a diverse digital therapeutics (DTx) portfolio by clinching a series of DTx deals. Bixink is a biotech subsidiary of KPS Corp. โฆSee details»
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive ...
Apr 30, 2020 Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Bixink Therapeutics, a new South Korean company working in the field of anti-cancer drugs โฆSee details»
BIXINK
BIXINKSee details»
Bixink Therapeutics - VentureRadar
Bixink Therapeutics is a biotech subsidiary of KPS Corp that focuses on building a diverse digital therapeutics (DTx) portfolio. The company has signed several DTx deals, including an โฆSee details»
MEDIA - BIXINK
Jul 20, 2022 Bixink Therapeutics signs deals to expand DTx pipelines Halimriadi Richar 24 May 2022 Views 5118 0; 12; Nerlynx in HER2-positive Early Breast Cancer, helping to overcome โฆSee details»
Boryung and Bixink to co-market Nerlynx for HER2-positive breast โฆ
Apr 4, 2024 Bixink Therapeutics has applied for health insurance benefits but has failed to get them. In the first year of its launch, Nerlynx reportedly generated 6 billion won in annual sales. โฆSee details»
How will Nerlynx affect HER2-positive early breast cancer โฆ
Jul 20, 2022 In 2021, Korean biotech firm Bixink Therapeutics introduced Nerlynx Tab. (neratinib), a HER2 inhibiting breast cancer treatment developed by Puma Biotechnology and โฆSee details»
BIXINK
Bixink Therapeutics, a start-up biopharmaceutical company that creates new treatment paradigms through creativity and innovation, is growing through strengthening its internal compliance โฆSee details»
MEDI:GATE NEWS ๋น ์ฝํฌ, ์ ๋ฐฉ์ ์ฐ์ฅ๋ณด์กฐ์๋ฒ ์น๋ฃ์ ๋๋ง์ค์ โฆ
Sep 21, 2022 ๋น ์ฝํฌํ ๋ผํจํฑ์ค(BIXINK THERAPEUTICS)๋ ์ ๋ฐฉ์ ์ ์ฝ '๋๋ง์ค(Nerlynx)'๊ฐ 2์ ์ถ์ ํ ์์ธ๋๋ณ์๊ณผ ์์ธ์์ฐ๋ณ์, ์ผ์ฑ์์ธ๋ณ์, ์ธ๋ธ๋์ค๋ณ์, ์์ธ์ฑ๋ชจ๋ณ์ ๋ฑ ๋น 5 โฆSee details»
Bixink Therapeutics - VentureRadar
Similar Companies: InStride Health USA Private InStride Health specializes in evidence-based outpatient treatment for pediatric anxiety and OCD. They offer a comprehensive approach that โฆSee details»
Bixink Therapeutics and Professional Dietetics enter into โฆ
Aug 5, 2021 Bixink Therapeutics and Professional Dietetics enter into partnership for the MUCOSAMIN® range, onco-supportive care, whereby Bixink will hold the exclusive โฆSee details»
Will Nerlynx satisfy unmet demand for early breast cancer in Korea ...
Jan 20, 2022 Bixink Therapeutics emphasized that Nerlynx is the nationโs first and only extended adjuvant therapy for HER2 positive early breast cancer. Park explained that the ultimate goal โฆSee details»
2025-04-28 Acquisition of US Biopharma Company SpringWorks โฆ
6 days ago SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only โฆSee details»
BIXINK
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer SymposiumSee details»